Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
US12084452B2 · kind B2 · utility
0Cited by
13References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 2, 2022 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Sep 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.